Emcure Pharmaceuticals

Last updated

Emcure Pharmaceuticals Limited
Company type Private
Industry Pharmaceutical
Founded1981;43 years ago (1981) [1]
FounderSatish Mehta
Headquarters Hinjawadi, Pune, India
Area served
Worldwide
Key people
RevenueIncrease2.svg5,812 crore (US$730 million) (FY22) [4]
Increase2.svg1,287 crore (US$160 million) (FY22) [4]
Increase2.svg702 crore (US$88 million) (FY22) [4]
Number of employees
11,000 (January 2022) [5]
Website emcure.com

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules) and injectables. [6] [7] The company is a major producer of HIV antivirals, as well as gynaecology and blood therapeutic drugs. [5]

Contents

Operations

Indian plants

This is the list of manufacturing facilities based in India [8] -

US plant

USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA. [8]

Investors

In 2014, Blackstone sold its 13% stake in Emcure to Bain Capital. [9]

AIDS initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [10] and Gilead Sciences for Tenofovir as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. [11] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version. [12]

Price fixing

Heritage Pharmaceuticals, a former division of Emcure, entered into a deferred prosecution agreement [13] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage agreed to pay a $225,000 fine. The DPA expired on May 30, 2022, and the United States District Court for the Eastern District of Pennsylvania dismissed with prejudice the one-count Information filed by the DOJ against Heritage on June 30, 2022.

In addition, Heritage separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, Heritage agreed to pay $7.1 million to the DOJ's Civil Division.

Controversies and recalls

There are allegations that Emcure (through its sister company Gennova) stole the technology of vaccine production by breaching contract with HDT Bio. [14] Earlier Emcure broke ties with Roche in similar way. [15]

The USFDA had given Warning Letter for data integrity manipulation problems at Emcure plants. [16]

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples. [11] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011. [17]

Even in the domestic market, Maharashtra FDA issued a circular to recall all the injections (500 mg /10 ml) manufactured by Emcure Pharmaceuticals Ltd, from across the country. [18]

Two injected drugs manufactured by Emcure, with a history of sterility problems were recalled because of microbial contamination. The drugs were both manufactured by Emcure Pharmaceuticals but were distributed in the U.S. by Heritage Pharmaceuticals (now renamed Avet). [19]

Related Research Articles

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Saquinavir</span> Chemical compound

Saquinavir, sold under the brand name Invirase among others, is an antiretroviral medication used together with other medications to treat or prevent HIV/AIDS. Typically it is used with ritonavir or lopinavir/ritonavir to increase its effect. It is taken by mouth.

Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Strides Pharma Science</span> Pharmaceutical company headquartered in India

Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore in southern India. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. Its softgel manufacturing capability consists of an annual capacity of 50,000 machine hours or about three billion softgel capsules. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. In the United States and Canadian markets, the company partners with generic companies to supply retail and hospital generics in injectable products and softgels. In European markets, it has long-term relationships for the development of projects and supply agreements with the European companies. In Australia and New Zealand, the company is engaged in manufacturing and supply of soft gels and value-added manufacturing. The company has development and supply agreements with South African companies. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacture of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<span class="mw-page-title-main">Prescription Drug User Fee Act</span> Legislation in the United States

The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process.

Unichem Laboratories is an Indian pharmaceutical company, headquartered in Mumbai. It manufactures and markets pharmaceutical formulations across the globe, including the regulated markets of the USA and Europe.

<span class="mw-page-title-main">Ipca Laboratories</span> Indian multinational pharmaceutical company

Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. It produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

<span class="mw-page-title-main">Aspen Pharmacare</span> Major pharmaceutical company in South Africa

Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.

<span class="mw-page-title-main">Taro Pharmaceuticals</span> Generic pharmaceutical company

Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer publicly listed in the New York Stock Exchange. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. The company's products are mainly sold in the United States, Canada and Israel. Taro Pharmaceutical Industries is reported to be on steady growth since 2008.

<span class="mw-page-title-main">Cadila Pharmaceuticals</span> Indian pharmaceutical company

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.

<span class="mw-page-title-main">Laurus Labs</span> Indian pharmaceutical company

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology. veterinary APIs and agro chemicals. The company was founded in 2005 by Dr. Satyanarayana Chava.

References

  1. "Emcure Pharmaceuticals Limited". CRISIL. Retrieved 3 January 2023.
  2. "Emcure Pharma inducts 4 independent directors". The Hindu. 27 July 2021. Retrieved 7 February 2023.
  3. "Shark Tank India Season 2: New shark joins the gang". Mint. 1 November 2022. Retrieved 2 November 2022.
  4. 1 2 3 "Emcure Pharmaceuticals Limited" (PDF). CARE Ratings. 6 January 2023. Retrieved 6 January 2023.
  5. 1 2 "Emcure Pharma's Rs 5,000-crore IPO to hit market early next month". Business Standard. 20 January 2022. Retrieved 3 January 2023.
  6. "Emcure Pharmaceuticals | Leading Global Pharmaceutical Company". Emcure. Retrieved 23 August 2021.
  7. "Emcure Pharmaceuticals". The Economic Times. Retrieved 23 August 2021.
  8. 1 2 "Manufacturing | Emcure Pharmaceuticals". Emcure. Retrieved 23 August 2021.
  9. "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express". archive.indianexpress.com.
  10. Bureau, Our Corporate (17 February 2006). "Bristol-Myers outsources AIDS drug to Emcure". Business Standard India via Business Standard.
  11. 1 2 "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times.
  12. "Roche to Sell Cheaper Cancer Drugs in India | Businessworld". Archived from the original on 1 August 2012. Retrieved 12 April 2012.
  13. "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". www.justice.gov. 31 May 2019.
  14. Brittain, Blake (22 March 2022). "Lawsuit says India's Emcure stole COVID-19 vaccine secrets for IPO". Reuters.
  15. "Roche, Emcure may end pact to make 2 blockbuster drugs". The Economic Times.
  16. Warning letter by USFDA - Data Integrity manipulation problem
  17. "March 2011". Archived from the original on 20 May 2011. Retrieved 25 April 2012.
  18. Orofer death
  19. FDA asks Emcure to recall contaminated injectable drugs